MX2024008642A - Composiciones de citocinas dise?adas y metodos de uso. - Google Patents
Composiciones de citocinas dise?adas y metodos de uso.Info
- Publication number
- MX2024008642A MX2024008642A MX2024008642A MX2024008642A MX2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- designed
- loop
- connects
- cytokine compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298623P | 2022-01-11 | 2022-01-11 | |
| US202363479178P | 2023-01-09 | 2023-01-09 | |
| US202363479177P | 2023-01-09 | 2023-01-09 | |
| US202363479176P | 2023-01-09 | 2023-01-09 | |
| PCT/US2023/060508 WO2023137346A2 (en) | 2022-01-11 | 2023-01-11 | Designed cytokine compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008642A true MX2024008642A (es) | 2024-09-23 |
Family
ID=87279672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008642A MX2024008642A (es) | 2022-01-11 | 2023-01-11 | Composiciones de citocinas dise?adas y metodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250223330A1 (https=) |
| EP (1) | EP4463469A4 (https=) |
| JP (1) | JP2025502205A (https=) |
| KR (1) | KR20240164594A (https=) |
| CN (1) | CN119053616A (https=) |
| AU (1) | AU2023208031A1 (https=) |
| CA (1) | CA3248134A1 (https=) |
| IL (1) | IL314226A (https=) |
| MX (1) | MX2024008642A (https=) |
| WO (1) | WO2023137346A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL325764A (en) * | 2023-07-13 | 2026-03-01 | Outpace Bio Inc | Designed compositions of interleukin-2 cytokine and methods of use |
| WO2025212606A1 (en) * | 2024-04-01 | 2025-10-09 | Bio-Techne Corporation | Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210025522A (ko) * | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| CN118510795A (zh) * | 2022-01-07 | 2024-08-16 | 苏州克睿基因生物科技有限公司 | 新型白介素-2多肽 |
-
2023
- 2023-01-11 WO PCT/US2023/060508 patent/WO2023137346A2/en not_active Ceased
- 2023-01-11 MX MX2024008642A patent/MX2024008642A/es unknown
- 2023-01-11 IL IL314226A patent/IL314226A/en unknown
- 2023-01-11 KR KR1020247026696A patent/KR20240164594A/ko active Pending
- 2023-01-11 AU AU2023208031A patent/AU2023208031A1/en active Pending
- 2023-01-11 JP JP2024541803A patent/JP2025502205A/ja active Pending
- 2023-01-11 US US18/727,646 patent/US20250223330A1/en active Pending
- 2023-01-11 CA CA3248134A patent/CA3248134A1/en active Pending
- 2023-01-11 EP EP23740805.9A patent/EP4463469A4/en active Pending
- 2023-01-11 CN CN202380027065.2A patent/CN119053616A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250223330A1 (en) | 2025-07-10 |
| KR20240164594A (ko) | 2024-11-19 |
| IL314226A (en) | 2024-09-01 |
| CA3248134A1 (en) | 2023-07-20 |
| EP4463469A2 (en) | 2024-11-20 |
| AU2023208031A1 (en) | 2024-08-29 |
| EP4463469A4 (en) | 2026-01-14 |
| WO2023137346A2 (en) | 2023-07-20 |
| JP2025502205A (ja) | 2025-01-24 |
| CN119053616A (zh) | 2024-11-29 |
| WO2023137346A3 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008642A (es) | Composiciones de citocinas dise?adas y metodos de uso. | |
| PH12021552162A1 (en) | Liquid composition comprising antibody of human interleukin-4 receptor alpha | |
| MX2026000396A (es) | Composiciones de citocinas interleucina-2 diseñadas y métodos para su uso | |
| EP4302826A3 (en) | Glucagon-like peptide 1 receptor agonists | |
| MX2023004349A (es) | Anticuerpos monoclonales anti-ccr8 y sus usos. | |
| MY199751A (en) | Anti-igf-i receptor antibody | |
| MX2024000611A (es) | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso. | |
| BR112021017365A2 (pt) | Receptores de citocina quiméricos constitutivamente ativos | |
| ZA202212500B (en) | Method of using a gip/glp1 co-agonist for diabetes | |
| WO2021188374A9 (en) | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides | |
| ZA202208051B (en) | Protein degradation agent compound preparation method and application | |
| NZ574473A (en) | Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity | |
| MX2023009995A (es) | Composiciones que incluyen adyuvantes de sbi y metodos para usarlos. | |
| MX2024003807A (es) | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos. | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| MX2026002776A (es) | Proteinas de union al antigeno biespecificas anti-receptor de cgrp/anti-receptor pac1 | |
| CO2021016619A2 (es) | Anticuerpos de receptor de péptido natriurético 1 y métodos de uso | |
| MX2024007393A (es) | Complejos polipeptidicos de union a antigeno activados condicionalmente y metodos de uso de los mismos. | |
| CA3156452A1 (en) | NPY2 RECEPTOR AGONISTS | |
| WO2020108629A8 (zh) | 一种多肽rdp1及其提纯方法与应用 | |
| CO2025009746A2 (es) | Antagonistas de citocinas multivalentes y multiespecíficos | |
| ZA202408121B (en) | Anti-human il-4ra antibody and application thereof | |
| BR112022007203A2 (pt) | Compostos imunogênicos para tratamento de câncer adrenal | |
| EP2431050A8 (en) | Methods of treating cancer using IL-21 and monoclonal antibody therapy | |
| ATE308335T1 (de) | Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese |